Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes

A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy

(2015) Masakazu Haneda et al.   Journal of Diabetes Investigation

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

(2014) Hala Yamout et al.   AMERICAN JOURNAL OF NEPHROLOGY

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans

(2013) M. A. Abdul-Ghani et al.   DIABETES

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

(2013) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

(2013) David Polidori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Effects of Sex and Age on Serum 1,5-anhydroglucitol in Nondiabetic Subjects

(2012) M. Ouchi et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Biology of Human Sodium Glucose Transporters

(2011) Ernest M. Wright et al.   PHYSIOLOGICAL REVIEWS

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

No Ghrelin Response to Oral Glucose in Diabetes Mellitus with Gastroparesis

(2009) Shiko ASAI et al.   ENDOCRINE JOURNAL

Renal Glucose Excretion and Tubular Reabsorption Rate Related to Blood Glucose in Subjects with Type 2 Diabetes with a Critical Reappraisal of the “Renal Glucose Threshold” Model

(2009) S. Wolf et al.   HORMONE AND METABOLIC RESEARCH

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM